Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610491 | 0.85 | SCN9A (0.39) | GAAEPHX1BTKSCN9ASCN3A | |
| SCHEMBL4630085 | 0.85 | SCN9A (0.39) | GAAEPHX1BTKSCN9ASCN3A | |
| SCHEMBL373560 | 0.80 | PRCP (0.43) | GAAEPHX1BTKSCN9ASCN3A | |
| SCHEMBL7299117 | 0.80 | PRCP (0.43) | GAAEPHX1BTKSCN9ASCN3A | |
| SCHEMBL28232408 | 0.80 | PRCP (0.43) | GAAEPHX1BTKSCN9ASCN3A | |
| SCHEMBL6433488 | 0.76 | SCN9A (0.36) | GAAEPHX1SCN9ASCN3ASCN5A | |
| SCHEMBL572824 | 0.76 | SCN9A (0.36) | GAAEPHX1SCN9ASCN3ASCN5A | |
| SCHEMBL926731 | 0.76 | SCN9A (0.36) | GAAEPHX1SCN9ASCN3ASCN5A | |
| SCHEMBL6872992 | 0.74 | PRCP (0.39) | GAAEPHX1BTKSCN9ASCN3A | |
| Hydrochloric Acid SCHEMBL28945847 | 0.74 | SCN9A (0.35) | GAASCN9ASCN3ASCN5APRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITRODMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | GAA 4226/4885EPHX1 115/4885BTK 2522/4885 |
| US-20070238735-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGS1 | GAA 4357/4885EPHX1 105/4885BTK 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.